Biomedtracker conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.
The United States (U.S.) market for stroke management products, which encompasses diagnostic and therapeutic systems, is a market composed of old and new technologies that are often used together in order to prevent and treat stroke. Improvements in stroke diagnostic systems will facilitate the delivery of timely stroke therapies within the optimum treatment window for patients suffering from stroke.
Bydureon (exenatide long-acting release; AstraZeneca) is a member of the glucagon-like peptide-1 (GLP-1) agonist class.
NovoEight (Novo Nordisk) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A.
Cimzia (certolizumab; UCB/Astellas [also marketed by Dermira in some approved indications]) is a PEGylated humanized monoclonal antibody fragment, with high affinity for both soluble and membrane-bound tumor necrosis factor alpha.
TS-1 (Otsuka/Nordic Group) is an orally available cytotoxic drug that contains gimeracil, oteracil potassium, and tegafur as active ingredients.
Drug Overview Farletuzumab is a folate receptor alpha (FRa)-targeted monoclonal antibody being developed by Eisai. It is composed of grafted murine complementarity-determining regions on a human IgG1 kappa backbone. Inhibiting FRa can decrease cellular proliferation through inhibition of both Lyn kinase substrate phosphorylation and the interaction between Lyn tyrosine kinase and membrane signaling complexes; effectively […]
Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature.
Empliciti is a MAb that targets the signaling lymphocytic activation molecule family, member 7 (SLAMF7), also called CS1.
Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2025.
Abemaciclib is a small molecule inhibitor of cyclin-dependent kinase (CDK)4 and CDK6 in Phase III development for non-small cell lung cancer and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer by Eli Lilly
This strategy report focuses Biosimilars Market Access in the US including the need for biosimilars, regulatory pathways, substitution and naming policy, legal issues, pricing, reimbursement, and market access.
Pharmaceutical companies constantly re-assess their pipelines and portfolios to determine the best strategies for their business.
The much-criticized delay in the removal of marketing authorization for Servier’s Mediator in France has had profound implications for reform of the country’s regulatory system.
This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union member state of the U.K.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!